Science 37 Inc

1. Retrophin, Inc. $7,429,419 196 payments
2. Moderna TX, Inc. $2,789,106 92 payments
3. Janssen Research & Development, LLC $1,409,104 29 payments
4. Amgen Inc. $769,058 1 payment
5. Baxter Healthcare $595,477 28 payments
6. Hill-Rom Company, Inc $455,907 4 payments
7. Genzyme Corporation $96,713 6 payments

1. A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency $2,177,833 45 payments
2. mRNA-1273-P922-Decentralized observational study to evaluate the immunogenicity of a Bivalent Booster as the seconddose against Omicron BA.4/5 $1,958,615 23 payments
3. An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) $1,167,260 25 payments
4. Evaluation of Oscillation and Lung Expansion (OLE) using The Volara System for treatment of respiratory complications in patients with neuromuscular disease in the home setting $1,051,385 32 payments
5. Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) $935,971 16 payments
6. An Open-Label, Phase 3 Long-Term Extension LTE Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria HCU due to Cystathionine Beta Synthase Deficiency ENSEMBLE $873,715 20 payments
7. Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency $850,783 27 payments
8. Prospective Longitudinal Study of Individuals at Risk of Developing Rheumatoid Arthritis $827,342 13 payments
9. Work Productivity Study $769,058 1 payment
10. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $695,653 49 payments

1. Other $5,168,523 129 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.